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Hepatitis C virus and kidney diseaseq
Paul Martin1,*, Fabrizio Fabrizi1,2
1Center for Liver Diseases, Miller School of Medicine, Department of Medicine, University of Miami, 1500 N.W. 12th Avenue,
Suite 1101-E, Miami, FL 33136, USA
2Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS Foundation, Milano, ItalyHepatitis C virus (HCV) infection remains frequent in patients on renal replacement therapy and has an adverse impact
on survival in infected patients on chronic hemodialysis as well as renal transplant (RT) recipients. Nosocomial spread of
HCV within dialysis units continues to occur. HCV is also implicated in the pathogenesis of renal dysfunction often med-
iated by cryoglobulins leading to chronic kidney disease as well as impairing renal allograft function. The role of antiviral
therapy for hepatitis C in patients with renal failure remains unclear. Monotherapy with conventional interferon (IFN) for
chronic hepatitis C is probably more eﬀective in dialysis than in non-uraemic patients but tolerance is lower. Limited data
only are available about monotherapy with pegylated interferon and combination therapy (pegylated IFN plus ribavirin)
for chronic HCV in the dialysis population. Clinical experience with antiviral therapy for acute HCV in dialysis population
is encouraging. Interferon remains contraindicated post-RT because of concerns about precipitating graft dysfunction.
Sustained viral responses obtained by antiviral therapy in renal transplant candidates are durable after renal transplanta-
tion and may reduce HCV-related complications after RT (post-transplant diabetes mellitus, HCV-related glomerulone-
phritis, and chronic allograft nephropathy).
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Patients with chronic kidney disease (CKD) on renal
replacement therapy especially hemodialysis (HD) con-
tinue to have a higher prevalence of hepatitis C virus
(HCV) infection than the general population. The prev-
alence of anti-HCV seropositivity in patients undergoing
regular dialysis in developed countries ranges between
7% and 40% [1–3].
Important insights gained in the last decade include
more accurate diagnostic testing for HCV in CKD and0168-8278/$34.00  2008 European Association for the Study of the Liver.
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rimental eﬀect of HCV on survival in dialysis patients
and renal transplant recipients has been conﬁrmed [4].
Despite these advances, the management of hepatitis C
virus-infected patients with CKD is complex and there
are several issues, such as the role of antiviral therapy
in dialysis patients and post-renal transplant that remain
unresolved. In addition, at least some patients develop
CKD as an extrahepatic manifestation of HCV. In
transplant recipients, renal injury has been described in
renal and hepatic recipients.
The aim of this paper is to review recent data on
HCV infection and CKD.2. Diagnosis of HCV infection
Serologic detection of antibody to HCV antigens by
enzyme-linked immunoassay (ELISA) remains thePublished by Elsevier B.V. All rights reserved.
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logical techniques there were some important concerns
about accurate diagnosis of HCV in patients with
CKD. The ﬁrst- and second-generation tests lead to fre-
quent false-negative results; Bukh et al. [5] reported that
2.6% of dialysis patients seronegative by second-genera-
tion ELISA were viremic by polymerase chain reaction
(PCR). The third-generation ELISA test however is
more speciﬁc and sensitive in patients with CKD. In
one series of 81 dialysis patients, no false-negative serol-
ogies were found [4]; however, in another report of 2576
patients, 6 (0.23%) were seronegative but PCR positive
[6]. Although the serological diagnosis of HCV in
CKD is now accurate, management decisions however
requires conﬁrmation of viremia and identiﬁcation of
speciﬁc genotype as well as assessment of viral load.
RIBA testing in CKD has generally been surpassed by
PCR-based technology which has been extensively eval-
uated in patients with CKD especially in the HD popu-
lation. Samples for HCV-RNA testing in dialysis
patients should be obtained prior to the HD procedure;
heparin used during dialysis sessions can interfere with
the PCR technique. In addition, the HD procedure
can lower HCV RNA levels by adsorption of HCV
RNA onto the inner surface of dialyzers and destruction
of viral particles by the hydraulic pressure exerted by the
blood for dialysis [7]. The HCV RNA qualitative assay
based on transcription mediated ampliﬁcation (TMA)
will probably increase sensitivity but it has been studied
in a relatively small number of CKD patients. The larg-
est series included 366 hemodialysis patients from
Greece [8]. The detection of HCV infection increased
with the use of sensitive HCV RNA (TMA) by 33.3%
(44/132). In another study, 22 HD patients (7%) were
negative by second-generation EIA but TMA positive
[9]. The development of two commercial real-time
PCR assays has facilitated the reproducible highly sensi-
tive detection of HCV RNA among diﬀerent laborato-
ries [10]. The clinical signiﬁcance of reduction in HCV
RNA levels during dialysis requires further evaluation
but has been suggested to be of potential beneﬁt if anti-
viral therapy is used [11].Table 1
HCV infection among patients undergoing long-term dialysis in devel-
oping countries: prevalence rates
Country Anti-HCV positives Reference year
Moldavia 75% (111/148) 1999
Egypt 80% (169/210) 2000
Saudi Arabia 43.4% (86/198) 2004
Iran 24.8% (74/298) 2005
Turkey 19% (83/437) 2005
Morocco 76% (141/186) 2005
Tunisia 20% (79/395) 2006
Brazil 16.4% (180/1095) 2007
Sudan 23.7% (56/236) 20073. Epidemiology of HCV in CKD patients (dialysis
population)
The advent of the serologic screening of blood for
HCV, the routine use of erythropoietin for CKD
patients with anemia, and the implementation of infec-
tion control procedures to prevent spread of HCV
within dialysis units has helped to reduce transmission
of HCV infection among patients on maintenance
hemodialysis in the developed world. The prevalence
of HCV infection patients on hemodialysis is variable
but is consistently higher than in the general population.Anti-HCV seropositive rate among patients on chronic
HD in the United States in 2002 was 7.8%
(n = 164,845), having been 10.4% in 1995 [1]. The prev-
alence of anti-HCV seropositive patients among patients
undergoing regular dialysis in Western Europe currently
ranges between 3% and 20% [1–4].
As shown in Table 1, information on the prevalence
and incidence of HCV infection in patients on long-term
dialysis in developing countries is limited but single-cen-
ter surveys show continued high prevalence and inci-
dence rates [12–14]. This probably reﬂects nosocomial
transmission of HCV in the HD environment, incom-
plete anti-HCV screening of blood and blood products,
and a higher prevalence of HCV in the general
population.4. Nosocomial transmission of HCV within HD units
The transmission of acute HCV among patients on
maintenance HD, despite the absence of typical paren-
teral risk factors, is supported by various observations:
an independent association between time on HD and
HCV seroprevalence [15], the relationship between prev-
alence and incidence of anti-HCV in individual HD
units [16], a higher frequency of anti-HCV seropositivity
in patients on HD at a hemodialysis center compared
with patients on peritoneal dialysis [17] and home-HD
treatment [18], and the relative homogeneity of HCV
isolates in patients receiving treatment in the same HD
unit [19]. The small but deﬁnite incidence of acute
HCV infection detected in chronic HD patients, after
the elimination of post-transfusion HCV, also conﬁrms
nosocomial HCV transmission.
Nosocomial HCV transmission among patients dia-
lyzed simultaneously in the same room has been unequiv-
ocally shown [20–24]. A total of 49 HD cases of acute
HCVwere identiﬁed over a 3-year follow-up in a Japanese
study [20]. The investigators observed that some nurses
withdrew needles for dialysis access in several consecutive
HD patients without changing gloves between patients.
After education of staﬀ members and application of an
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cases of acute HCV were recognized for more than 1 year
in 730 patients on regular HD. Kokubo et al. [21] sug-
gested that sharing of contaminated multidose vials of
heparin-saline solutions was responsible for an HCV out-
break in their HD unit. Poor hand washing before and,
less frequently, after activities which involved a risk of
nosocomial transmission was described by Arenas et al.
[25] as an important cause of HCV spread in HD. These
authors also carried out a multicenter survey to evaluate
the extent of compliance with standard precautions by
HD staﬀ in nine Spanish HD units [26]. Hand washing
was performed only 13.8% of the time before patient con-
tact, and 35.6% of the time after patient contact. Gloves
were actually usedon92.9%of occasions indicated byunit
policy.
The transmission of HCV between patients receiving
hemodialysis on the same day on diﬀerent shifts but
sharing the same HD machine is consistent with trans-
mission possibly via dialysis machines but appears
uncommon [27]. Dialyzer reuse has been identiﬁed as a
risk factor for seroconversion for HCV in a Portugese
study. In units that reprocessed dialyzes, centers that
used a separate room to reprocess dialyzers from anti-
HCV-positive patients, and those that did not reprocess
dialyzers from anti-HCV-positive patients had signiﬁ-
cantly lower incidence rates compared with those that
did not follow any speciﬁc precautions [28]. It remains
unclear whether this reﬂected a causal relationship or
a better adherence to infection control practices in cen-
ters with a separate room for reuse (or no reuse) in
HCV-infected dialysis patients.
There is no consensus about the need to isolate HCV-
infected patients on maintenance HD by rooms,
machines and staﬀ analogous to HBsAg positive
patients on regular hemodialysis. Hepatitis C and B
(HBV) viruses are parenterally transmitted, and the iso-
lation of HBsAg positive patients has been successful in
limiting spread of HBV within HD units. However, a
need to isolate is not universally accepted. The infectiv-
ity of HCV is lower than HBV, and the virus is not via-
ble at room temperature. Two large prospective studies
have addressed the impact of isolation measures on
HCV transmission to hemodialysis patients [2,22]. No
signiﬁcant link between nosocomial transmission of
HCV to hemodialysis patients and absence of isolation
was noted. A Belgian prospective multicenter study
eliminated nosocomial spread of HCV (from 1.4% to
0%) over a 54-month follow-up in the absence of any
isolation policy but by close attention to blood-borne
precautions [29]. A similar reduction was achieved by
others [30]. The CDC does not recommend designated
machines or patient isolation; no ban on dialyzer reuse
has been advocated [31,32]. A strict adherence to stan-
dard precautions and routine HD unit precautions fully
prevents HCV transmission to HD patients.5. Natural history of HCV in CKD patients (dialysis
population)
Accurate assessment of the natural history of HCV in
dialysis patients and renal transplant recipients has been
diﬃcult as infection in these patients is typically asymp-
tomatic with an apparently indolent course. Dialysis
patients generally have high morbidity and mortality
rates reﬂecting age and comorbid conditions making
the long-term consequences of HCV infection diﬃcult
to determine. Routine evaluation of HCV infection is
further complicated in CKD by aminotransferase values
which are typically lower in the dialysis than in the non-
uraemic population. Dialysis patients with HCV viremia
have aminotransferase levels greater than those who do
not, although values remain within the so-called ‘normal
range’ [33].
However, studies with appropriate size and follow-up
have shown an independent and signiﬁcant association
between anti-HCV positivity and diminished patient
survival [34–37]. A recent meta-analysis on the impact
of HCV on mortality (seven observational studies
involving 11,589 unique patients on maintenance
hemodialysis) showed that the summary estimate for
adjusted relative risk (RR) of all-cause mortality with
anti-HCV was 1.34 with a 95% conﬁdence interval of
1.13–1.59 [38]. Liver dysfunction has been implicated
in a lower survival of seropositive patients; the summary
estimate for RR of liver-related mortality with anti-
HCV was 3.75 (95% CI, 1.93; 17.99) [38].
A more recent association with cardiovascular mor-
tality has been identiﬁed with an independent and signif-
icant link between anti-HCV serologic status and
cardiovascular mortality; the relative risk was 1.80
(95% CI, 1.1–2.95) in the subset of patients younger
than 65 years [37]. This multivariate analysis was
adjusted for case-mix and malnutrition-inﬂammation
complex syndrome variables, which are associated with
mortality.6. Natural history of HCV in CKD patients (renal
transplant recipients)
The most important causes of death after RT are car-
diovascular disease, infection, and malignancy but liver-
related deaths also play a role in increased mortality
after renal transplant. Initial studies did not show a sig-
niﬁcant diﬀerence in survival for anti-HCV-positive RT
recipients, particularly when 5-year but not 10-year sur-
vival rates were reported. Mathurin et al. [39] retrospec-
tively studied 834 RT recipients over a 10-year follow-up
period. No survival diﬀerences were seen at 5 years.
However, at 10 years, patient and graft survival of
HCV-infected patients were signiﬁcantly lower than
those described in uninfected matched RT controls,
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(P = 0.001) and 49% ± 5% vs. 69% ± 4% for graft sur-
vival (P < 0.01), respectively]. A recent meta-analysis
of observational studies [40] has conﬁrmed that positive
anti-HCV antibody status was an independent and sig-
niﬁcant risk factor for death and graft failure after
RT; the summary estimate for RR was 1.79 (95% CI,
1.57; 2.03) and 1.56 (95% CI, 1.35; 1.80), respectively.
In addition to an increased disease burden due to
liver disease, HCV infection in the kidney transplant
recipient has been implicated in the pathogenesis of
acute glomerulopathy [41], de novo immune complex
glomerulonephritis in the allograft [42–44], and a higher
rate of chronic allograft nephropathy [45]. HCV has also
been linked to an increased incidence of diabetes melli-
tus following renal transplantation (PTDM) [46].7. Liver biopsy data in CKD
There is a lack of liver biopsy data in patients with
HCV and CKD. Glicklich et al. [47] found that the total
histological score and stage were similar between 22
patients on the waiting list for RT and 45 RT recipients
seropositive for anti-HCV. There were no patients with
cirrhosis, and only three with stage 3 ﬁbrosis in the sub-
group of renal transplant candidates. In 37 anti-HCV
seropositive patients with chronic renal failure who were
referred for kidney or kidney/liver transplantation, cir-
rhosis was present in 25% (9/37), and some degree of
ﬁbrosis in 81% (30/37). No relationship between severity
of histologic changes and HCV viral load or genotype or
aminotransferase activity was apparent. In this study
[48], there was a high frequency of patient referral for
combined kidney/liver transplantation perhaps account-
ing in part for the frequency of advanced ﬁbrosis. Ster-
ling et al. [49] evaluated liver histology in 50 consecutive
patients with chronic HCV awaiting RT. Bridging ﬁbro-
sis or cirrhosis was present in 22%, which was not signif-
icantly diﬀerent from a control group of HCV-positive
patients with intact renal function and normal ALT,
although there was a trend towards more ﬁbrosis in
the dialysis group. These studies suggest that advanced
ﬁbrosis is a common histologic ﬁnding in individuals
otherwise believed to be acceptable RT candidates
despite ‘normal’ aminotransferase values. As in other
studies of HCV in CKD, patients evaluated for possible
RT are generally a more robust cohort than dialysis-
dependent patients as a whole. Patients with clinically
overt liver disease might be precluded from RT evalua-
tion, perhaps helping to underestimate the consequences
of HCV in CKD. The role of non-invasive evaluation of
liver ﬁbrosis in HCV-infected patients with CKD
requires further study. The Fibroscan machine which
is currently undergoing clinical evaluation appears use-
ful at excluding cirrhosis in patients with chronic liverdisease [50] and may have a role in CKD patients with
HCV infection.
As cirrhosis constitutes an important risk factor for
death and renal dysfunction after renal transplantation
alone, combined kidney/liver transplantation should be
considered for renal transplant candidates with cirrhosis
even without overt hepatic decompensation. The
recently published KDIGO guidelines from the Internal
Society of Nephrology suggest that isolated renal trans-
plant may be a reasonable consideration in patients with
well compensated cirrhosis [51].8. Kidney donor with HCV-positive serology
HCV can also be transmitted from infected donors to
recipients by kidney transplantation [52,53]. A number
of mechanisms have been suggested to explain the vari-
ance in reported transmission rates: prevalence of HCV
viremia among cadaveric donor pools, viral load, and
recipient susceptibility. The rate of HCV transmission
has been much higher using slush perfusion of organs
than in those using pulsatile perfusion [54].
The prevalence of a positive second-generation anti-
HCV test among U.S. cadaver organ donors was 4.2%
in 1992 [55]. The high prevalence of HCV among dialy-
sis patients awaiting RT and the shortage of cadaveric
kidneys led some groups to evaluate eﬃcacy and safety
of using kidneys from HCV-infected donors in recipients
already infected with HCV [56,57]. This approach short-
ened waiting times for these patients and did not aﬀect a
short-term survival or invariably lead to progressive
liver disease. In contrast, a large registry analysis dem-
onstrated that use of grafts from HCV-infected donors
was associated with a high rate of mortality, regardless
of the anti-HCV antibody status of the recipient [58].
This study, although large, is limited by the absence of
information on recipient baseline liver disease or comor-
bidity, or the rationale for use an HCV-infected donor
kidney. Transplantation of kidneys from donors
infected with HCV should be restricted to recipients
with positive HCV viremia at the time of transplant.
The UNOS database indicates that the use of kidneys
from anti-HCV-positive deceased donors in HCV-
infected recipients is associated with superior patient
survival compared to remaining on dialysis [59]. The
potential risks of superinfection with an HCV donor
genotype diﬀerent from that of the recipient is unknown.
Genotype superinfection through transplantation has
been reported in a few cases and a 10-fold increase in
transaminase levels was observed [60,61]. Recently, a
multicenter survey found no impact on patient or graft
survival [62]. In contrast, use of organs from HCV-posi-
tive donors has been unequivocally associated with
severe acute hepatitis in HCV naı¨ve recipients and is
contraindicated [52].
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(dialysis patients)
9.1. Monotherapy with standard interferon
Monotherapy with standard IFN in HCV-infected
patients on maintenance hemodialysis has been evalu-
ated in numerous albeit generally small clinical trials
[63–79] [Table 2], only a few of which were controlled
[66,69,73]. A recent meta-analysis identiﬁed 24 trials
(529 unique patients) demonstrating that the summary
estimate of the sustained virological response (SVR)
was 39% (95% CI, 32; 46), and 33% (95% CI, 19; 47)
for genotype 1 [80]. Paradoxically sustained viral
responses are higher in patients on maintenance hemod-
ialysis compared to patients with intact kidney function.
Several mechanisms may account for this observation:
dialysis patients with HCV usually have a lower viral
load, liver disease may be milder [46], and a release of
endogenous interferon during hemodialysis sessions
has been described [81]. Further, there is impaired clear-
ance of standard interferon in patients on maintenance
hemodialysis [82,83].
However, tolerance to interferon monotherapy is
lower in patients on maintenance hemodialysis with a
drop-out rate of 19% (95% CI, 13; 26) [80]. The proﬁle
of side-eﬀects to interferon therapy in dialysis patients
seems diﬀerent from normal controls; in addition to
ﬂu-like symptoms (17%), other common side-eﬀects
leading to interruption of interferon therapy in dialysis
patients are neurological (21%), and gastrointestinal
(18%).
It is unproven whether achieving an SVR translates
into improved survival in the CKD population with
HCV infection. However, SVR results in improved liver
histology [63,73]. Huraib et al. [73] observed that histo-
logic activity index (HAI) score decreased from
4.27 ± 1.19 to 1.64 ± 0.67 (P = 0.0001) after IFN-alpha
treatment in 15 hemodialysis patients on a cadaveric
renal transplant list who underwent repeated liver
biopsy (before and at the end of IFN-a treatment). PolTable 2
Antiviral therapy (monotherapy by standard IFN) of chronic hepatitis C
in dialysis patients: SVR (sustained virological response) rate according
to ITT (intention-to-treat) analysis
SVR Country
Koenig et al. (1994) 30% (11/37) Austria
Casanovas-Taltavull et al. (2001) 62% (18/29) Spain
Degos et al. (2001) 19% (7/37) France
Kamar et al. (2003) 38% (21/55) France
Ozdemir et al. (2004) 40% (8/20) Turkey
Rivera et al. (2005) 40% (8/20) Spain
Yildirim et al. (2006) 54% (20/37) Turkey
Buargub et al. (2006) 25.7% (9/35) Libya
Rocha et al. (2006) 21% (10/46) Brazil
Only large-size (nP 20 patients) trials were reported.et al. have recently given standard IFN to three dialysis
patients with HCV-related cirrhosis; tolerance to treat-
ment was satisfactory and liver histology in two of them
improved signiﬁcantly [84].
However, there is concern about the applicability of
these results to all dialysis patients since most subjects
in these studies were on the waiting list for RT and were
probably more robust than the general HD population.
Only limited information is available from North Amer-
ican centers where many CKD patients are African-
American which is a predictor of impaired response to
interferon [85].
9.2. Combined (standard interferon plus ribavirin)
antiviral therapy
The elimination rate of ribavirin in patients with
impaired renal function is reduced, and only a small
fraction of the drug is eliminated by hemodialysis. A
lack of information about appropriate ribavirin dosing
and concerns about side-eﬀects, i.e. severe hemolytic
anemia, have limited the use of ribavirin in dialysis
patients [86–88]. In a concentration-controlled study,
Bruchfeld et al. [87] used combined therapy in six dialy-
sis patients: the SVR was 17% (one of six). Average daily
doses were 170–300 mg ribavirin. Ribavirin-induced
anemia was treated with high doses of erythropoietin
(20,000–30,000 IU/week).
Others [88] have given standard IFN plus ribavirin
(200 mg 3/week) for 24 weeks to nine patients on
maintenance HD with a SVR of 66% (six out of nine).
In another 11 patients the SVR rate was 55% (six out
of 11). No additional side-eﬀects were reported at this
lower ribavirin dose.
9.3. Monotherapy with pegylated interferon
No signiﬁcant diﬀerences in apparent body clearance
of peg-IFN a-2a between patients with normal kidney
function and those with signiﬁcant reductions in kidney
function (creatinine clearance > 100 mL/min vs. 20–
40 mL/min) have been detected [89]. However, the phar-
macokinetics of pegylated interferon a-2a during
hemodialysis may vary reﬂecting permeability and dia-
lyzer pore size [90].
A single dose pharmacokinetic study of pegIFN a-2b
found its mean area under the serum concentration-time
curve and Cmax (maximum concentration in serum) was
increased up to twofold in patients with renal failure
compared with controls; mean half-life increased by up
to 40% [91]. In a separate analysis of hemodialysis
patients in the same study, it was observed that the
HD procedure had negligible eﬀects on clearance. A sin-
gle dose study in patients on maintenance hemodialysis
identiﬁed no additional toxicity although there was a
30% reduction in IFN clearance [92].
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patients on chronic HD (n = 78) treated with pegIFN-
a2a (135 mcg s.c. weekly) was reported by Covic et al.
[93]. The SVR rate was 14.1% (11/78) and a high rate
of adverse eﬀects (83%) was recorded.
As listed in Table 3, the use of pegylated interferon is
mostly based on small uncontrolled clinical trials [94–
102].
9.4. Combined (pegylated interferon plus ribavirin)
antiviral therapy
Information on combined antiviral therapy is even
more preliminary in nature [103–106]. Bruchfeld et al.
[103] administered pegIFN plus ribavirin to dialysis
patients, four patients were given pegIFN-a2b and two
pegIFN-a2a. Average ribavirin dose was 170–300 mg/
day. The SVR and drop-out rate were 50% (three out
of six) and 50% (three out of six), respectively.
The successful management of ribavirin-induced ane-
mia in dialysis patients has been described by Rendina
et al. [104] in a prospective, controlled trial. The SVR
rate was 97.5% (34/35) in chronic hemodialysis patients
receiving peginterferon alfa-2a (135 mcg/week) plus
ribavirin (200 mg/day) for 24 or 48 weeks (according
to HCV genotype). One patient discontinued therapy
prematurely due to anemia, and 26 (74%) required the
epoietin-alfa dose to be increased to 40,000 IU/week
up to the end of the study. Eleven (31%) patients
required reduction of the ribavirin dosage (from
200 mg/day to 200 mg on every other day). The high
SVR and tolerance reﬂected several factors including
study design. Only young patients on the waiting list
for renal transplant were included; most patients had
mild liver disease [52% (12/23)].Table 3
Antiviral therapy based on pegylated IFN (alone or with ribavirin) for
chronic hepatitis C in dialysis patients: SVR rate (sustained virological
response) according to ITT (intention-to-treat) analysis
SVR Antiviral agent
Annichiarico et al. (2004) 33.3% (2/6) Peg-IFNa-2b
Teta et al. (2005) 66.6% (2/3) Peg-IFNa-2a
Russo et al. (2006) 12.5% (2/16) Peg-IFNa-2b
Sporea et al. (2006) 30% (3/10) Peg-IFNa-2a
Mukherjee et al. (2003)* 22.2% (2/9) Peg-IFNa-2b
Covic et al. (2006) 14.1% (11/78) Peg-IFNa-2a
Casanovas-Taltavull
et al. (2007)
25% (3/12) Peg-IFNa-2a
Ayaz et al. (2008) 50% (11/22) Peg-IFNa-2a
Li et al. (2008) 48% (12/25) Peg-IFNa-2a
Bruchfeld et al. (2006) 50% (3/6) Peg-IFNa-2a + R (n = 2)
Peg-IFNa-2b + R (n = 4)
Rendina et al. (2007) 97% (34/35) Peg-IFNa-2a + R
Van Leusen et al. (2008) 71% (5/7) Peg-IFNa-2a + R
* Study limited to patients with chronic renal failure (not on dialysis)
with recurrent hepatitis C after OLT.Less impressive results were reported by Carriero
et al. [106] in a prospective, cohort trial with pegIFN-
a2a plus low-dose ribavirin (200 mg/day) for chronic
HCV in 15 patients receiving long-term dialysis. The
SVR and drop-out rate were 29% (4/14) and 71% (10/
14), respectively. The most frequent side-eﬀect was ane-
mia which required ribavirin discontinuation in three
patients; seven (47%) patients received blood
transfusion.10. Therapy of chronic HCV in CKD population (renal
transplant recipients)
No safe and eﬀective therapy exists for the treatment
of chronic HCV post-RT [107–110]. A meta-analysis of
clinical trials of IFN-based therapy (interferon alone or
with ribavirin) in RT recipients with chronic hepatitis C
showed that the summary estimate for SVR and drop-
out rate was 18.0% (95% CI, 7.0–29%) and 35% (95%
CI, 20–50%), respectively [111]. The most frequent
side-eﬀect requiring interruption was graft dysfunction,
typically acute rejection refractory to corticosteroid
therapy.
Combined antiviral therapy (interferon plus ribavi-
rin) has been used in a few studies. Shu et al. [109] trea-
ted 11 RT recipients with chronic HCV with a very low
dose of IFN-a (1 MU by subcutaneous route three times
weekly) for 48 weeks. Three patients terminated the
therapy prematurely because of acute graft failure (one
case) and urosepsis (two cases). Antiviral therapy with
interferon needs to be considered only in patients [i.e.,
ﬁbrosing cholestatic hepatitis (FCH)] in whom the risk
of not treating justiﬁes the possible loss of the allograft.
Alternative regimens based on drugs other than inter-
feron have been described but no proof of their eﬃcacy
has been provided. Amantadine [112], ribavirin mono-
therapy [113,114] or their combination [115] had no
impact on viral levels or liver histology.11. Therapy of chronic HCV in CKD population (renal
transplant candidates)
There is increasing interest in treating HCV infection
in RT candidates. Kamar et al. [116] treated 55 anti-
HCV positive/HCV RNA positive hemodialysis patients
with standard interferon monotherapy, 21 (38%) had an
SVR. Of these, 16 (76%) underwent renal transplanta-
tion and received immunosuppressive therapy, including
antithymocyte globulin. At 22.5 months after renal
transplantation, HCV viremia was absent in all patients,
and no patient developed PTDM. A case report also
reported a patient with a durable SVR post-RT [117].
Pre-transplant interferon may also reduce the occur-
rence of post-transplant de novo or recurrent glomerulo-
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transplant recipients who received pre-renal transplanta-
tion interferon, 10 (67%) became negative at the time of
renal transplantation, and only one of 15 (6.7%) devel-
oped de novo glomerulonephritis (this patient was
HCV RNA positive at transplantation). Among
untreated controls, 12 out of 60 (19%) developed de novo
glomerulonephritis post-RT, all 12 had detectable HCV
RNA at transplantation.
Pre-transplant antiviral therapy of HCV may lower
the incidence of post-transplant diabetes mellitus
(PTDM) in allograft recipients. In a controlled trial,
Gursoy et al. [119] observed that the frequency of
PTDM was higher in the group of HCV-positive recip-
ients who had not received IFN than in those who had
been treated with IFN before transplantation, 25%
(10/40) vs. 7.1% (1/14), P = 0.009.
An additional beneﬁt of pre-transplant antiviral ther-
apy may be a reduced incidence of chronic allograft
nephropathy (CAN) as HCV infection has been impli-
cated in its pathogenesis. In a large group of kidney
transplant recipients with chronic HCV, Mahmoud
et al. [45] found that a higher proportion of untreated
controls developed chronic allograft nephropathy com-
pared with IFN patients, 40.6% (13/32) vs. 5.6% (1/
18), P = 0.009. The SVR rate was 44% (8/18) and 0%
(0/32), in IFN-treated and control group, respectively
(P < 0.05). By multivariate analysis, absence of IFN
therapy before RT was a risk factor for chronic allograft
nephropathy with an odds ratio of 11.6 (P = 0.020).12. Therapy of acute HCV in CKD population (dialysis
patients)
Acute HCV progresses to chronic infection in more
than 90% of uremic patients [120,121]. Recent recom-
mendations to monitor ALT in HD population may
facilitate detection of cases of acute HCV [122–128].
In a prospective, controlled clinical trial Gursoy et al.
[123] administered low- (3 MU) and high-dose (6–
10 MU) IFN-a2a three times weekly for 3 months to
36 patients on regular hemodialysis with acute HCV.
The SVR rate was 53% (19/36); six (16%) patients dis-
continued therapy as a result of side-eﬀects. Three
(50%) patients in the high-dose group had to stop ther-
apy as a result from severe ﬂu-like symptoms (n = 2),
and leukopenia (n = 1). Viral clearance was observed
in one patient (5.6%) of the control group.
In a controlled clinical trial, Al-Harby et al. [127]
administered IFN-a (3 MU three times per week) for
12 weeks to nine adult patients with acute hepatitis
C – six (67%) achieved an SVR. Two patients in the
treatment group dropped out; one due to colitis and
another because of non-compliance. No patients in the
control group had RNA clearance. Based on these data,treatment of acute HCV if recognized should be
attempted.13. Therapy of HCV in CKD patients (HCV-associated
glomerulonephritis)
Recent information at a population-based level has
shown a signiﬁcant link between HCV seropositivity
and an increased risk for developing ESRD [129]. The
role of HCV infection in glomerular diseases has been
conﬁrmed in both native and transplanted kidneys
[130]. The most common form of kidney disease associ-
ated with HCV is type I membranoproliferative glomer-
ulonephritis (MPGN) in patients with type II
cryoglobulinemia. The majority of trials of antiviral
therapy for HCV-related GN have conﬁrmed a relation-
ship between SVR and improvement in kidney function
[131–135]. Rossi et al. [132] treated using combined ther-
apy (standard IFN plus ribavirin, 12 months) three
patients with HCV-related cryoglobulinemic GN. All
patients achieved an SVR and a decrease of daily pro-
teinuria (3.47 ± 1.5 vs. 0.17 ± 0.12, P = 0.02) and rheu-
matoid factor [1320 (210–2142) vs. 112 (99–266) IU/mL]
on follow-up.
A recent meta-analysis of clinical, controlled trials
of the two treatments (antiviral versus immunosuppres-
sive) described for HCV-related GN [136] identiﬁed six
studies involving 145 unique patients with HCV-associ-
ated GN [137–142]. The majority of patients had cryo-
globulinemic glomerulonephritis. The primary end-
point was the frequency of patients with reduction of
proteinuria (return of proteinuria to normal or
decrease >50%) at the end of therapy. Pooling of study
results demonstrated that proteinuria decreased more
commonly after standard IFN-doses than corticoste-
roid therapy, OR was 3.86 (95% CI, 1.44; 10.33;
P = 0.007). The conclusion was that standard-IFN
doses were more eﬀective than immunosuppressive
therapy in lowering proteinuria of patients with
HCV-related cryoglobulinemic GN at least in the short
term.
Preliminary data support the use of rituximab, a
human-mouse chimeric monoclonal antibody that is
highly eﬀective for in vivo B-cell depletion, for the treat-
ment of HCV-associated GN. It has been suggested that
rituximab interferes with monoclonal IgM production,
cryoglobulin synthesis, and renal deposition of immune
complexes (ICs). Two uncontrolled, pilot trials have
been conducted (n = 11 patients) [143,144]. A decrease
in proteinuria was found in both the trials with a con-
comitant reduction of serum levels of rheumatoid factor.
No acute or delayed severe side-eﬀects were seen. How-
ever, clinical relapses of glomerular disease after comple-
tion of rituximab therapy were found. Response is not
universal [145].
620 P. Martin, F. Fabrizi / Journal of Hepatology 49 (2008) 613–62414. Conclusions and recommendations
Despite screening of blood products nosocomial
transmission of HCV continues to occur in HD units.
HCV infection diminishes patient and graft survivals.
Therapy of HCV in CKD is complicated but SVR can
reduce post-RT complications. Antiviral treatment of
HCV-related GN can result in improvement in renal
function.
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